Fasinumab
- Generic Name
- Fasinumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190239-42-9
- Unique Ingredient Identifier
- 11T51Q3082
- Background
Fasinumab is a human IgG1k monoclonal antibody targeted against nerve growth factor (NGF). It is currently under investigation for the treatment osteoarthritic pain and has demonstrated significantly greater pain relief and functional improvement as compared to standard therapy (i.e. NSAIDs and/or opioids) in this patient population.
...
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip
- Conditions
- Interventions
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT03949673
- Locations
- π΅π±
Regeneron Recruting SIte, Bialystok, Poland
π¬π§Regeneron Research Site, Liverpool, United Kingdom
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
- Conditions
- Interventions
- First Posted Date
- 2018-10-02
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT03691974
- Locations
- π¬π§
Regulatory Study Site, London, United Kingdom
π¬π§Regeneron Study Site, Waterloo, United Kingdom
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1650
- Registration Number
- NCT03304379
- Locations
- πΊπΈ
Advance Research Center, Anaheim, California, United States
πΊπΈCatalina Research Institute, LLC, Montclair, California, United States
πΊπΈClinical Research Advantage, Inc./Warner Family Practice, PC, Chandler, Arizona, United States
Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee
- Conditions
- Interventions
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT03285646
- Locations
- πΊπΈ
Regeneron Research Site #1, Memphis, Tennessee, United States
πΊπΈRegeneron Research Site, Kenosha, Wisconsin, United States
πΊπΈRegeneron Research Site #2, Memphis, Tennessee, United States
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 3307
- Registration Number
- NCT03161093
- Locations
- πΊπΈ
Pacific Arthritis Care Center, Los Angeles, California, United States
πΊπΈLynn Institute of the Rockies, Colorado Springs, Colorado, United States
πΊπΈPanorama Orthopedics & Spine Center, Golden, Colorado, United States
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 5331
- Registration Number
- NCT02683239
- Locations
- πΊπΈ
Regeneron Investigational Site (4 locations), Phoenix, Arizona, United States
π¬π§Regeneron Investigational Site, Sidcup, United Kingdom
πΊπ¦Regeneron Investigational Site #1, Kyiv, Ukraine
A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain
- First Posted Date
- 2015-12-02
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 563
- Registration Number
- NCT02620020
Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects
- First Posted Date
- 2015-08-06
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 72
- Registration Number
- NCT02516618
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.